The diagnosis, prognosis, and therapeutic application of MicroRNAs in haematological malignancies

References

• Liu X, Liu L, Xu Q, Wu P, Zuo X, Ji A. MicroRNA as a novel drug target for cancer therapy. Expert Opin Biol Ther. 2012; 12(5): 573–80. doi: 10.1517/14712598.2012.671293
   PubMed Web of Science ®Google Scholar
• Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012; 6(6): 590–610. doi: 10.1016/j.molonc.2012.09.006
   PubMed Web of Science ®Google Scholar
• Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2013; 93(1): 98–104. doi: 10.1038/clpt.2012.192
   PubMed Web of Science ®Google Scholar
• Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006; 13(12): 1097–101. doi: 10.1038/nsmb1167
   PubMed Web of Science ®Google Scholar
• Landthaler M, Yalcin A, Tuschl T. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol. 2004; 14(23): 2162–7. doi: 10.1016/j.cub.2004.11.001
   PubMed Web of Science ®Google Scholar
• Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003; 17(24): 3011–6. doi: 10.1101/gad.1158803
   PubMed Web of Science ®Google Scholar
• Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 2000: 404(6775): 293–6. doi: 10.1038/35005107
   PubMed Web of Science ®Google Scholar
• Georgantas RW, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S, et al. CD34 + hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A. 2007; 104(8): 2750–5. doi: 10.1073/pnas.0610983104
   PubMed Web of Science ®Google Scholar
• Gerrits A, Walasek MA, Olthof S, Weersing E, Ritsema M, Zwart E, et al. Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. Blood. 2012; 119(2): 377–87. doi: 10.1182/blood-2011-01-331686
   PubMed Web of Science ®Google Scholar
• Masaki S, Ohtsuka R, Abe Y, Muta K, Umemura T. Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun. 2007; 364(3): 509–14. doi: 10.1016/j.bbrc.2007.10.077
   PubMed Web of Science ®Google Scholar
• Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008; 132(5): 875–86. doi: 10.1016/j.cell.2008.02.019
   PubMed Web of Science ®Google Scholar
• Joshi D, Gosh K, Vundinti BR. MicroRNAs in hematological malignancies: a novel approach to targeted therapy. Hematology. 2012; 17(3): 170–5. doi: 10.1179/102453312X13376952196656
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang D, Du W, Gu D, Yang R. MicroRNA and leukemia: tiny molecule, great function. Crit Rev Oncol Hematol. 2010; 74(3): 149–55. doi: 10.1016/j.critrevonc.2009.05.001
   PubMed Web of Science ®Google Scholar
• McIver AD, East P, Mein CA, Cazier JB, Molloy G, Chaplin T, et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukemia. PloS One. 2008; 3(5): e2141. doi: 10.1371/journal.pone.0002141
   PubMed Web of Science ®Google Scholar
• Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008; 105(40): 15535–40. doi: 10.1073/pnas.0808266105
   PubMed Web of Science ®Google Scholar
• Lavrencic MJ, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008; 111(10): 5078–85. doi: 10.1182/blood-2008-01-133355
   PubMed Web of Science ®Google Scholar
• Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, et al. Sp1/NF-ĸB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010; 17(4): 333–47. doi: 10.1016/j.ccr.2010.03.008
   PubMed Web of Science ®Google Scholar
• Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Cymering CF, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A. 2008b; 105(10): 3945–50. doi: 10.1073/pnas.0800135105
   PubMed Web of Science ®Google Scholar
• Oorschot AAD, Kuipers JE, Peters SA, Schotte D, Haas Vd, Trka J, et al. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2012; 58(5): 715–21. doi: 10.1002/pbc.23279
   PubMed Web of Science ®Google Scholar
• Fazi F, Rosa A, Fatica A, Gelmetti V, Marchis MLD, Nervi C, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBP alpha regulates human granulopoiesis. Cell. 2005; 123(5): 819–31. doi: 10.1016/j.cell.2005.09.023
   PubMed Web of Science ®Google Scholar
• Johnnidis JB, Harris MH, Wheeler RT, Sun SS, Lam MH, Kirak O, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008; 451(28): 1125–9. doi: 10.1038/nature06607
   PubMed Web of Science ®Google Scholar
• Pulikkan JA, Dengler V, Peramangalam PS, Zada AAP, Tidow CM, Bohlander SK, et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood. 2010a; 115(9): 1768–78. doi: 10.1182/blood-2009-08-240101
   PubMed Web of Science ®Google Scholar
• Garzon R, Volinia S, Liu CG, Cymering CF, Palumbo T, Pichiorri F, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008; 111(6): 3183–9. doi: 10.1182/blood-2007-07-098749
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008; 26(31): 5078–87. doi: 10.1200/JCO.2008.17.5554
   PubMed Web of Science ®Google Scholar
• Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007; 104(50): 19971–6. doi: 10.1073/pnas.0709313104
   PubMed Web of Science ®Google Scholar
• Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, et al. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009; 4(11): e7826. doi: 10.1371/journal.pone.0007826
   PubMed Web of Science ®Google Scholar
• Schotte D, Chau JC, Sylvester G, Liu G, Chen C, Velden VH, et al. Identification of new microRNA genes and aberrant micro-RNA profiles in childhood acute lymphoblastic leukemia. Leukemia. 2009; 23(2): 313–22. doi: 10.1038/leu.2008.286
   PubMed Web of Science ®Google Scholar
• Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Siqueira RP, Jr WAS, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res. 2007; 40(11): 1435–40. doi: 10.1590/S0100-879X2007001100003
   PubMed Web of Science ®Google Scholar
• Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2009; 113(2): 396–402. doi: 10.1182/blood-2008-07-163907
   PubMed Web of Science ®Google Scholar
• O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 1998; 17(2): 384–95. doi: 10.1093/emboj/17.2.384
   PubMed Web of Science ®Google Scholar
• Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008; 9(4): 405–14. doi: 10.1038/ni1575
   PubMed Web of Science ®Google Scholar
• Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic dissection of the miR-17-92 cluster of microRNAs in Myc induced B-cell lymphomas. Genes Dev. 2009; 23(24): 2806–11. doi: 10.1101/gad.1872909
   PubMed Web of Science ®Google Scholar
• Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cardo CC, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009; 23(24): 2839–49. doi: 10.1101/gad.1861409
   PubMed Web of Science ®Google Scholar
• J-Eneriz ES, R-Gomez J, J-Velasco A, Garate L, Martin V, Cordeu L, et al. MicroRNA expression profiling in Imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2008; 8: 69. doi: 10.1186/1476-4598-8-69
   Web of Science ®Google Scholar
• Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010; 17(1): 28–40. doi: 10.1016/j.ccr.2009.11.019
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39): 13944–49. doi: 10.1073/pnas.0506654102
   PubMed Web of Science ®Google Scholar
• Chen RW, Bemis LT, Amato CM, Myint H, Tran H, Birks DK, et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood. 2008; 112(3): 822–9. doi: 10.1182/blood-2008-03-142182
   PubMed Web of Science ®Google Scholar
• Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 2007; 109(11): 4944–51. doi: 10.1182/blood-2006-12-062398
   PubMed Web of Science ®Google Scholar
• Dijkstra MK, Lom KV, Tielemans D, Elstrodt F, Langerak AW, van 't Veer MB, et al. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia. 2009; 23(3): 625–7. doi: 10.1038/leu.2008.264
   PubMed Web of Science ®Google Scholar
• Zhao JN, Lu QY, Zhu JF, Fu J, Chen YX. Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagn Pathol. 2014; 9: 76. doi: 10.1186/1746-1596-9-76
   PubMed Web of Science ®Google Scholar
• Lin X, Wang Z, Zhang R, Feng W. High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia. Clin Transl Onc. 2015; 17(5): 358–64. doi: 10.1007/s12094-014-1237-z
   PubMed Web of Science ®Google Scholar
• Chen XX, Lin J, Qian J, Qian W, Yang J, Ma JC, et al. Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. Clin Biochem. 2014; 47(1–2): 63–6. doi: 10.1016/j.clinbiochem.2013.09.020
   PubMed Web of Science ®Google Scholar
• Nemes K, Csoka M, Nagy N, Márk Á, Váradi Z, Dankó T, et al. Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia. Pathol Oncol Res. 2015; 21(3): 597–604. doi: 10.1007/s12253-014-9861-z
   PubMed Web of Science ®Google Scholar
• Eneriz ESJ, Roman-Gomez J, Jimenez-Velasco A, Garate L, Martin V, Cordeu L, et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABLI-mutations. Mol Cancer. 2009; 8: 69. doi: 10.1186/1476-4598-8-69
   PubMed Web of Science ®Google Scholar
• Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, et al. Expression of the miR-17–92 polycistron in chronic myeloid leukemia (CML) CD34 + cells. Blood. 2007; 109(10): 4399–405. doi: 10.1182/blood-2006-09-045104
   PubMed Web of Science ®Google Scholar
• Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010; 140(5): 652–65. doi: 10.1016/j.cell.2010.01.007
   PubMed Web of Science ®Google Scholar
• Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010; 95(8): 1325–33. doi: 10.3324/haematol.2009.020636
   PubMed Web of Science ®Google Scholar
• Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Invest. 2013; 123(6): 2395–407. doi: 10.1172/JCI66553
   Google Scholar
• Emmrich S, K-Kuipers J, Henke K, Khatib ME, Jammal R, Engeland F, et al. miR-9 is a tumor suppressor in pediatric AML with t(8;21). Leukemia. 2014; 28(5): 1022–32. doi: 10.1038/leu.2013.357
   PubMed Web of Science ®Google Scholar
• Hong JN, Yu J, Lin HS, Zhang XH, Yin XL, Xiao Z, et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ. 2014; 21(1): 100–12. doi: 10.1038/cdd.2013.141
   PubMed Web of Science ®Google Scholar
• H-Rokah O, Modai S, P-Chor M, Toren A, Shomron N, Raanani P, et al. MiR-30e induces apoptosis and sensitises K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett. 2014; 356(2): 597–605. doi: 10.1016/j.canlet.2014.10.006
   PubMed Web of Science ®Google Scholar
• Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev. 2003; 17(4): 438–42. doi: 10.1101/gad.1064703
   PubMed Web of Science ®Google Scholar
• McNamara J, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006; 24(8): 1005–15. doi: 10.1038/nbt1223
   PubMed Web of Science ®Google Scholar
• Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005; 23(6): 709–17. doi: 10.1038/nbt1101
   PubMed Web of Science ®Google Scholar
• Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002; 16(8): 948–58. doi: 10.1101/gad.981002
   PubMed Web of Science ®Google Scholar
• Yamada N, Noguchi S, Kumazaki M, Shinohara H, Miki K, Naoe T, et al. Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukemia Jurkat cells by modulating expression of Fas-associated protein with death domain (FADD). Biochim Biophys Acta. 2014; 1843(3): 590–602. doi: 10.1016/j.bbamcr.2013.11.022
   PubMed Web of Science ®Google Scholar
• Leeuw D, Denkers F, Olthof M, Rutten AP, Pouwels W, Schuurhuis GJ, et al. Attenuation of microRNA-126 expression that drives CD34 + 38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res. 2014; 74(7): 2094–105. doi: 10.1158/0008-5472.CAN-13-1733
   PubMed Web of Science ®Google Scholar
• Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther. 2007; 15(12): 2070–9. doi: 10.1038/sj.mt.6300311
   PubMed Web of Science ®Google Scholar
• Ebert MS and Sharp PA. Emerging roles for natural microRNA sponges. Curr Biol. 2010; 20(19): R858–61. doi: 10.1016/j.cub.2010.08.052
   PubMed Web of Science ®Google Scholar
• Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol. 2007; 212(2): 285–92. doi: 10.1002/jcp.21062
   PubMed Web of Science ®Google Scholar
• Agirre X, V-Zornoza A, J-Velasco A, M-Subero JI, Cordeu L, Gárate L, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009; 69(10): 4443–53. doi: 10.1158/0008-5472.CAN-08-4025
   PubMed Web of Science ®Google Scholar